Roundtable Discussion: Designing Safer Molecules & Feasible Formulations Earlier to Reduce Off-Target Risk & Improve Development Viability
- Using AI, big data and in silico design to predict receptor selectivity, reducing unexpected off-target effects, to improve confidence before costly clinical investment
- Assessing systemic exposure, metabolite risks and tissuespecific safety liabilities, anticipating unpredictable toxicities, to avoid late-stage failures seen with dermatology standards such as retinoic acid
- Balancing sophisticated formulation design with manufacturability and cost, ensuring preclinical innovation remains commercially viable, to support realistic pipeline progression